2.2. Study arms and treatment plans
After carefully reviewing the COVID-19 patients records based on the
hospital information database, and finally considering the inclusion and
exclusion criteria, 183 patients were divided into two groups; 109
patients have received standard treatment and 74 patients have received
IVIG (Figure1).
In this study, epidemiological, demographic, clinical, laboratory data,
management, and outcomes of patients were obtained. Finally, the
outcomes include mortality rate, duration of hospitalization, mechanical
ventilation and ICU length of stay were analyzed and compared between
two groups.
The standard treatment group regimen was oral Hydroxychloroquine (HCQ)
400 mg daily for 5 days plus Atazanavir/Ritonavir (300/100) daily for
ten days. IVIG treatment was divided into three groups of low, medium
and high dose (0.25, 0.5 and 1 gr/ kg) during 3-5 consecutive days in
addition to standard care.